ifn 2

Anti-Mouse IFN gamma Antibody (R4-6A2) 为小鼠特异性抗IFNγ抗体，源自大鼠，属于IgG1kappa 类型。其同型对照为 RatIgG1kappa, Isotype Control。

2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) 是细胞天然免疫中第二信使，在 DNA 结合条件下由 cGAMP 合成酶 (cGAS) 催化形成。2',3'-cGAMP sodium 可与 STING 结合形成二聚体，诱导 IFN-β 及其他细胞因子的产生和表达。

Deucravacitinib (BMS-986165) 是一种高选择性、口服生物可利用的变构 TYK2 抑制剂，用于治疗自身免疫性疾病。它通过稳定调节 JH2 结构域来阻断受体介导的 Tyk2 激活，可抑制IL-12 23和 I 型IFN 途径。它选择性结合 TYK2 假激酶 (JH2) 结构域，IC50为1.0 nM。

2-NP 是选择性的STAT1转录增强剂。它能够增强 IFN-γ 的功能，提高对人乳腺癌和纤维肉瘤细胞增殖的抑制能力。

IFN alpha-IFNAR-IN-1 hydrochloride 是 IFN-α 和 IFNAR 相互作用的抑制剂。 IFN alpha-IFNAR-IN-1 hydrochloride 抑制 BM-pDCs 的 MVA 诱导的 IFN-α 反应，IC50 为 2-8 μM。

2',3'-cGAMP (2'-3'-cyclic GMP-AMP) 是细胞天然免疫中第二信使，在DNA结合条件下由 cGAMP 合成酶 (cGAS) 催化形成。2',3'-cGAMP 可与 STING 结合形成二聚体，诱导干扰素-β（IFN-β）及其他细胞因子的产生和表达。

RO8191 (CDM-3008) 是干扰素 (IFN) 受体激动剂。它直接与 IFNα β 受体 2 结合，激活 IFN 刺激的基因表达和 JAK STAT 磷酸化。它通过具有干扰素样活性发挥 cccDNA 调节剂作用，并具有抗 HBV 活性。

Ginsenoside F3 是一种皂苷，提取自Panax ginseng 叶片。它能够调节1 型 (IL-2, IFN-γ) 及 2 型细胞因子(IL-4 and IL-10) 的产生和表达，有免疫增强的作用。

Ethyl Caffeate (ETHYL 3,4-DIHYDROXYCINNAMATE) 是从鬼针草分离的一种酚类天然产物，在体外或在小鼠皮肤中抑制NF-κB 活化及其下游炎症介质的诱导型一氧化氮合酶、环氧合酶 2 和前列腺素 E2。

IFN alpha-IFNAR-IN-1 is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR. It inhibits MVA-induced IFN-α responses by BM-pDCs (IC50: 2-8 μM).

DD205-291, 作为一种PROTAC HPK1降解剂，展现出口服活性，其DC50值仅为5.3 nM。此化合物能有效抑制SLP-76的磷酸化并诱导IL-2与IFN-γ的产生。

6,6′-Trehalose dioleate（6,6′-TDO）是一种被广泛用于mRNA体内外递送的糖脂化合物。它能高效包裹流感A病毒血凝素A（HA）编码的mRNA，在脂质纳米粒子（LNPs）中使用，用于增强隔离小鼠脾细胞分泌Ifn-γ, Il-2和Tnf-α。在肌肉注射进入小鼠体内后，包含6,6′-TDO的LNPs主要在肝脏与脾脏中集中。区别于未含6,6′-TDO的LNP配方，这种LNPs不会引起血清中血尿素氮（BUN）、乳酸脱氢酶（LDH）、肌钙蛋白I、丙氨酸氨基转移酶（ALT）、及天门冬氨酸氨基转移酶（AST）水平的改变。此外，该LNPs还能提升小鼠血清中IgG1与IgG2a抗体的滴度。

KRN7000 analog 8 (compound 8) 是 KRN7000 的类似物，与KRN7000相比，它能够有效刺激IL-2的产生，同时诱导较少的IFN-γ，但提升IL-4的产量。

BRD0476 is a suppressor of pancreatic β-cell apoptosis. BRD0476 inhibits interferon-gamma (IFN-γ)-induced Janus kinase 2 (JAK2) and signal transducer and activation of transcription 1 (STAT1) signaling to promote β-cell survival. BRD0476 inhibits JAK-STAT

Ingenol 3,20-dibenzoate is a powerful activator of protein kinase C (PKC) isoforms. It effectively induces the translocation of nPKC-delta, -epsilon, and -theta as well as PKC-mu from the cytosolic fraction to the particulate fraction. Through de novo synthesis of macromolecules, it triggers apoptosis with characteristic morphology. Moreover, Ingenol 3,20-dibenzoate enhances IFN-γ production and degranulation in NK cells, particularly when stimulated by NSCLC cells[1][2].

Benpyrine is a highly specific and orally active TNF-α inhibitor with a KD value of 82.1 μM. Benpyrine tightly binds to TNF-α and blocks its interaction with TNFR1, with an IC50 value of 0.109 μM. Benpyrine has the potential for TNF-α mediated inflammatory and autoimmune disease research[1]. Benpyrine (5-20 μM; 14 hours; RAW264.7 cells) pretreatment results in a dose-dependent decrease in the phosphorylation of IκBα in RAW264.7 cells (stimulated with 10 ng mL TNF-α or 1 μg mL LPS). Benpyrine abolishes the TNF-α-induced nuclear translocation of NF-κB p65 in RAW264.7 cells[1].Benpyrine only blocks cell death induced by TNF-αWT and Y119A, and increases the cell survival rate up to 80%. Benpyrine does not obviously affect L57A- and Y59L-induced cytotoxicity in L929 cells[1]. Benpyrine (25-50 mg kg; oral gavage; daily; for 2 weeks; Balb c mice) treatment significantly relieves the symptoms of collagen-induced arthritis. Benpyrine dose-dependently decreases the levels of proinflammatory cytokines, such as IFN-γ, IL-1β and IL-6, and increases the concentration of the anti-inflammatory cytokine IL-10[1].Endotoxemia murine model shows that Benpyrine (25 mg kg) could attenuate TNF-α-induced inflammation, thereby reducing liver and lung injury[1]. [1]. Weiguang Sun, et al. Discovery of an Orally Active Small Molecule TNF-α Inhibitor. J Med Chem. 2020 Jul 15.

NG 25 is a type II kinase inhibitor that inhibits MAP4K2 and TAK1 (IC50s = 21.7 and 149 nM, respectively).1It also inhibits the Src family kinases Src and LYN (IC50s = 113 and 12.9 nM, respectively) and Abl family kinases (IC50s = 75.2 nM), as well as CSK, FER, and p38α (IC50s = 56.4, 82.3, and 102 nM, respectively). NG 25 (100 nM) prevents TNF-α-induced IKKα/β phosphorylation and IκB-α degradation in L929 cells. It inhibits secretion of IFN-α and IFN-β induced by CpG type B and CL097, respectively, in Gen2.2 cells in a concentration-dependent manner.2NG 25 decreases cell viability of HCT116KRASWT, and to a greater degree of HCT116KRASG13D, colorectal cancer cells in a concentration-dependent manner.3It also reduces tumor growth and increases the number of TUNEL-positive tumor cells in a CT26KRASG12Dmouse orthotopic model of colorectal cancer. 1.Tan, L., Nomanbhoy, T., Gurbani, D., et al.Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)J. Med. Chem.58(1)183-196(2015) 2.Pauls, E., Shpiro, N., Peggie, M., et al.Essential role for IKKβ in production of type 1 interferons by plasmacytoid dendritic cellsJ. Biol. Chem. 287(23)19216-19228(2012) 3.Ma, Q., Gu, L., Liao, S., et al.NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivoApoptosis24(1-2)83-94(2019)

MSA-2 dimer is a selective, orally active non-nucleotide STING agonist (Kd=145 μM) with long-term antitumor and immunogenic activity. MSA-2 dimer is bound to STING as a non-covalent dimer exhibiting higher permeability than cyclic dinucleotide[1]. MSA-2 dimer (60 mg kg; p.o.; 50 days) inhibits tumor growth and prolongs overall survival[1]. MSA-2 dimer (40 mg kg; s.c.; 25 days) induces complete tumor regression[1].MSA-2 dimer (60 mg kg; p.o.; 4 hours) increases proinflammatory cytokine (IFN-β) level in tumors[1].MSA-2 dimer (60 mg kg; s.c.; 4 hours) concentrations is observed in tumors than in plasma or other nontumor tissues [1].MSA-2 dimer (THP-1 cells) induces phosphorylation of both TBK1 and IR. MSA-2 dimer (10 μM and 33 μM; macrophages) induces IFN-β[1].MSA-2 dimer also exhibits dose-dependent antitumor activity when administered by IT, SC, or PO routes[1]. [1]. Pan BS, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020;369(6506):eaba6098.

PE(18:1(9Z) 0:0) 是一种天然存在的溶血磷脂，是缩醛磷脂溶血磷脂酰乙醇胺的类似物。 PE(18:1(9Z) 0:0) 以浓度依赖性方式诱导 PC12 大鼠神经元细胞中细胞内钙的瞬时增加。 PE(18:1(9Z) 0:0) 增加 IL-4 和 IL-2 的产生，但不增加 IFN-γ 的产生。 在小鼠血清中，PE(18:1(9Z) 0:0)（1 μg 动物）诱导 T 辅助细胞 2 反应。 在寒冷暴露三天后，小鼠肩胛间棕色脂肪组织中的 PE(18:1(9Z) 0:0) 水平增加。

Ganglioside GM1 asialo is a component of cellular lipid rafts and can be formed by the cleavage of the sialic acid residue from ganglioside GM1 by neuraminidase. Ganglioside GM1 asialo is a glycolipid receptor for P. aeruginosa flagellin and stimulates defensive responses in host cells, including extracellular ATP release, calcium mobilization, and ERK1/2 phosphorylation when stimulated by flagellin and an anti-ganglioside GM1 asialo antibody. The percentage of ganglioside GM1 asialo-positive natural killer (NK) and CD8+ T cells in lung is increased in a mouse model of respiratory syncytial virus (RSV) infection compared with healthy animals. Depletion of ganglioside GM1 asialo-positive NK and T cells reduces IFN-γ levels in the lung, reduces weight loss, and increases lung viral load in RSV-infected mice. Ganglioside GM1 asialo mixture contains ganglioside GM1 asialo molecular species with C18:1 and C20:1 sphingoid backbones.

PROTAC IDO1 Degrader-1 is the first potent IDO1 (indoleamine 2,3-dioxygenase 1) degrader that hijacks IDO1 to CRBN E3 ligase to introduce IDO1 into UPS and eventually achieve ubiquitination and degradation (DC50=2.84 μM). PROTAC IDO1 Degrader-1 moderately improves the tumor-killing activity of H ER2 CAR-T cells[1]. PROTAC IDO1 Degrader-1 (compound 2c) (10 μM; 24 hours) notably decreases IDO1 level induced by IFN-γ[1].PROTAC IDO1 Degrader-1 and IFN-γ (5 ng mL) are incubated with HeLa cells for 24 h, and a significant dose-dependent degradation is observed. PROTAC IDO1 Degrader-1 combined with chimeric antigen receptor-modified T (CAR-T) cells can improve the tumor-killing activity of HER-2 CAR-T cells[1].PROTAC IDO1 Degrader-1 induces significant and persistent degradation of IDO1 with maximum degradation (dmax) of 93% in HeLa cells[1]. [1]. Hu M, et al. Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1. Acta Pharm Sin B. 2020;10(10):1943-1953.

KBC-007 is a synthetic branched chain-containing analog of α-galactosylceramide (α-GalCer). It induces IL-4 and IFN-γ secretion by mouse splenocytes when used at a concentration of 0.5 ng/ml and IL-2 secretion by DN32.D3 NKT hybridoma cells co-cultured with CD1d-transfected RBL cells pre-loaded with KBC-007 at a concentration of 8 ng/ml. KBC-007 (1 μg per animal) increases levels of IL-4, but not IFN-γ, to a similar degree as α-GalCer in mouse serum. KBC-007 (0.5 μg per animal) increases the survival rate of mice immunized with the inactivated influenza A virus A/PR/8/34 in a model of influenza infection.

Jaceosidin 是从毛莲蒿中得到的一种黄酮类天然产物，可激活Bax，下调 Mcl-1 和 c-FLIP 的表达，诱导癌细胞凋亡。它能够降低炎性因子水平，激活 NF-κB，抑制COX-2的表达，具有抗癌和抗炎作用。

Neobavaisoflavone 是一种从Psoralea corylifolia 的种子中分离出来的类黄酮。它具有抗炎，抗癌和抗氧化的作用。它在中至高浓度下可抑制 DNA 聚合酶，也可抑制血小板聚集。